Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma

Area of Science:

• Cardiovascular Medicine
• Rheumatology
• Hematology

Background:

• Platelet activation plays a role in vascular injury and repair.
• Elevated markers like circulating platelet aggregates and beta-thromboglobulin indicate platelet activation.
• Scleroderma is a complex autoimmune disease with potential vascular involvement.

Purpose of the Study:

• To investigate platelet activation in patients with scleroderma.
• To assess levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma patients compared to controls.
• To evaluate the effect of antiplatelet therapy on these markers in scleroderma.

Main Methods:

• Studied 38 scleroderma patients and 18 age/sex/race-matched controls.
• Measured circulating platelet aggregates (% of total platelet count).
• Quantified plasma beta-thromboglobulin levels.

Main Results:

• Scleroderma patients showed significantly higher circulating platelet aggregates (31.2% vs 7.2%, p<0.0005).
• Beta-thromboglobulin levels were also significantly elevated in scleroderma patients (72.7 ng/mL vs 20 ng/mL, p<0.0005).
• A positive correlation (r=0.6, p<0.0005) existed between platelet aggregates and beta-thromboglobulin; therapy reduced both.

Conclusions:

• Scleroderma is associated with in-vivo platelet activation and release of platelet granule constituents.
• Antiplatelet therapy (dipyridamole and aspirin) normalized these markers in treated patients.
• Further research is needed to determine the long-term impact of antiplatelet therapy on scleroderma progression.